Selective PRR Agonist Prodrugs for Targeted RIG-I Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The systemic administration of RIG-I agonists risks inducing systemic inflammation due to the ubiquity of RIG-I expression in virtually all cell types, leading to potential dose-limiting toxicities and restricted therapeutic applications.
Innovation Solution
Development of selective pattern recognition receptor (PRR) agonists comprising nucleic acid agonists conjugated with macromolecules via environmentally sensitive linkers, allowing for controlled activation of RIG-I by cleaving the conjugated macromolecule in response to specific environmental stimuli, thereby minimizing systemic activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RIG-I agonists are administered systemically, then immunostimulatory activity is achieved, but systemic inflammation and toxicity occur
Solution Approach 1:
The agonist is segmented into two functional parts: a nucleic acid component that provides immunostimulatory activity and a macromolecule component that provides steric blocking activity. The macromolecule is conjugated to the nucleic acid via a cleavable linker, creating a segmented structure where each component performs its specific function. This segmentation allows the agonist to remain inactive during systemic circulation (macromolecule blocks PRR binding) and become active only at the target site (after linker cleavage separates the components).
Solution Approach 2:
The macromolecule is pre-conjugated to the nucleic acid agonist to block PRR binding activity before administration. This preliminary blocking action prevents systemic inflammation during circulation. The blocking macromolecule is attached via a cleavable linker that will be broken at the target site, releasing the blocked agonist to become active. This preliminary action of blocking ensures safety during systemic distribution while maintaining the potential for later activation.
2Object-affected harmful factors
If RIG-I agonists are administered topically or intratumorally, then localized activation is achieved, but therapeutic applications are restricted
Solution Approach 1:
The invention changes the key parameter of agonist activation from location-dependent (requiring topical or intratumoral administration) to condition-dependent (activated by linker cleavage). By using a cleavable linker that responds to specific biochemical conditions (such as enzymatic cleavage or pH changes) rather than requiring physical localization, the agonist can be administered systemically and will activate under controlled conditions. This parameter change expands therapeutic versatility while maintaining localized activation benefits.
3Object-affected harmful factors
If macromolecule is conjugated to nucleic acid agonist, then PRR binding is blocked, but agonist activity is reduced
Solution Approach 1:
A cleavable linker serves as an intermediary between the macromolecule and the nucleic acid agonist. This intermediary component allows the macromolecule to block PRR binding during circulation while providing a mechanism for controlled separation. The linker acts as a temporary bridge that maintains the blocked state during distribution but can be broken to release the active agonist at the target site. This intermediary enables both the blocking function and the subsequent activation function without permanently reducing agonist activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables targeted and selective activation of the RIG-I pathway, reducing systemic inflammation and toxicity, while maintaining immunostimulatory activity, thus expanding therapeutic applications and improving safety.
Implementation Method 1
conjugated with macromolecules via environmentally sensitive linkers, allowing for controlled activation of RIG-I by cleaving the conjugated macromolecule in response to specific environmental stimuli
Data Source
AI summary
Provided herein are a selective pattern recognition receptor (PRR) agonist and a method of selectively activating a PRR. The selective PRR agonist includes a nucleic acid agonist and a macromolecule conjugated to the nucleic acid agonist. The method includes administering the selective PRR agonist to a subject, and cleaving at least a portion of the macromolecule conjugated to the nucleic acid agonist, the cleaving of at least a portion of the macromolecule permitting the agonist to bind a PRR.